17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
by on Tuesday, August 14th, 2012 | No Comments
Conditions: Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: bortezomib; Drug: tanespimycin
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Completed – verified August 2009
Here is the original post: 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas